Publication of NE3107 nonclinical safety and human pharmacokinetics

San Diego, June 14, 2017 — NeurMedix, Inc., a clinical-stage biopharmaceutical company that engages in developing products for the treatment of neurological and neuro-degenerative disorders, today announced the Publication of NE3107 nonclinical safety and human pharmacokinetics.


- Summary of publication abstract: NE3107 (HE3286) long-term safety in animals and clinical pharmacokinetics were published. NE3107 metabolism in rodents was different than in dogs and humans. NE3107 and metabolites did not bind steroid binding nuclear hormone receptors or inhibit P450 enzymes. There were no adverse effects in safety pharmacology and chronic dosing canine toxicology studies. In humans NE3107 drug exposure was dose proportional, the terminal half-life was 8 hours in males and 5.5 hours in females.

- Significance (Clarence Ahlem, Chief Operating Officer): NE3107 is the first derivative of the dehydroepiandrosterone metabolome to undergo a comprehensive pharmacological and safety evaluation. The results of this extensive series of studies show no dose limiting toxicities for NE3107, and remove potential regulatory barriers to extended dosing protocols in clinical trials.